文献速递瓣膜外科

保留左室功能且无心衰症状的重度二尖瓣反流:修复与置换对比

Mitral valve repair versus replacement for patients with preserved left ventricular function without heart failure symptoms.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-09-26

本研究基于纽约州42家医院2008至2014年2259例连续患者,比较保留心室功能且无充血性心力衰竭症状的重度二尖瓣反流患者接受二尖瓣修复(1801例,79.7%)与置换的结局。倾向性匹配显示修复组4年死亡率显著更低(3.5% vs 12.1%,P < .001),再手术、心衰或卒中再入院率无差异。高手术量外科医生更倾向于选择修复。

要点

  • 保留心室功能且无心衰症状的重度二尖瓣反流患者,修复较置换4年死亡率更低。
  • 修复与置换在再手术、心衰或卒中再入院率上无显著差异。
  • 高手术量外科医生更常选择二尖瓣修复,但各手术量分位间死亡率无差异。

核心结论

  • 对于保留心室功能且无充血性心力衰竭症状的慢性重度原发性二尖瓣反流患者,二尖瓣修复较置换带来更低的4年死亡率,且再手术、心衰或卒中再入院率无差异。
  • 应尽可能将二尖瓣修复作为这类患者的外科选择。

研究设计与样本

  • 基于纽约州42家医院强制性全州临床登记数据,纳入2008年1月1日至2014年12月31日期间2259例连续患者,其中二尖瓣修复1801例(79.7%),余接受置换。
  • 采用倾向性匹配比较死亡率,竞争风险分析比较非致命结局,中位随访4.0年。

主要发现

  • 倾向性匹配后,二尖瓣修复组4年死亡率显著低于置换组(3.5% vs 12.1%,P < .001)。
  • 修复与置换在再手术、充血性心力衰竭或卒中再入院率方面无显著差异。
  • 手术量越大的外科医生越倾向于实施二尖瓣修复(最高手术量分位92%,其余分位分别为84%、74%和69%)。
  • 不同手术量分位间死亡率无显著差异。

临床怎么用

  • 对于慢性重度原发性二尖瓣反流、左心室功能保留且无充血性心力衰竭症状的患者,应优先考虑二尖瓣修复而非置换。
  • 外科医生选择修复的比例随手术量增加而提高,但手术量并未影响死亡率,提示应推动修复技术的推广。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The purposes of this study are to compare outcomes of mitral valve repair (MV-repair) and mitral valve replacement for patients with severe mitral regurgitation with preserved ventricular function and no congestive heart failure (CHF) symptoms and to examine variations in surgeon choice of procedure and outcomes by surgeon volume. METHODS: In total, 2259 consecutive patients in 42 New York State hospitals with the characteristics mentioned previously who underwent mitral valve repair (1801, 79.7%) or replacement between January 1, 2008, and December 31, 2014, were identified from a mandatory statewide clinical registry. Propensity-matching was used to compare mortality and competing risk analyses were used to compare nonfatal outcomes. Median follow-up was 4.0 years. The use of mitral repair and risk-adjusted mortality for surgery were also examined as a function of individual surgeon mitral case volume. RESULTS: Propensity-matched patients who underwent MV-repair experienced a significantly lower mortality rate at 4 years (3.5% vs 12.1%, P < .001). Greater-volume surgeons were more likely to perform MV-repairs (92% vs 84%, 74%, and 69% in lower volume quartiles, respectively). No significant differences in mortality were observed among volume quartiles. CONCLUSIONS: Patients with chronic severe primary mitral valve regurgitation with preserved ventricular function and no CHF symptoms who underwent MV-repair experienced lower mortality and no different reoperation, CHF, or stroke readmission rates than patients who underwent replacement. Greater-volume surgeons were more likely than their lower volume counterparts to choose mitral repair. Repair should be considered as the surgical option for these patients whenever possible.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hannan EL, Samadashvili Z, Smith CR, et al. Mitral valve repair versus replacement for patients with preserved left ventricular function without heart failure symptoms. J Thorac Cardiovasc Surg. 2018. PMID: 30482532. doi:10.1016/j.jtcvs.2018.08.091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。